These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4022207)

  • 21. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance.
    McCaleb ML; Izzo MS; Lockwood DH
    J Clin Invest; 1985 Feb; 75(2):391-6. PubMed ID: 3882760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Separation, isolation and amino acid composition of uremic peptides.
    Shaykh M; Dubin A; Dunea G; Mamdani B; Ahmed S
    Clin Physiol Biochem; 1984; 2(1):1-13. PubMed ID: 6488692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shortened purification procedure of a spleen-derived immunosuppressive peptide.
    Lenfant M; Millerioux-Di Giusto L; Masson A; Gasc JC
    J Chromatogr; 1981 Feb; 206(1):177-80. PubMed ID: 7217277
    [No Abstract]   [Full Text] [Related]  

  • 24. Isolation, purification and partial characterization of early pregnancy factor (EPF) from sera of pregnant women.
    Haq A; Mothi BA; Al-Hussein K; Al-Tufail M; Hollanders J; Jaroudi K; Al-Waili N; Shabani M
    Eur J Med Res; 2001 May; 6(5):209-14. PubMed ID: 11410402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effect of peak 2-4 of uremic middle molecules on platelet aggregation.
    Palés JL; López A; Asensio A; Merola E; Company X; Deulofeu R; Garcia M; Balagué A
    Eur J Haematol; 1987 Sep; 39(3):197-202. PubMed ID: 3678470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amino acid composition of uremic middle and low molecular weight retention products.
    Bazilinski N; Shaykh M; Ahmed S; Musiala T; Williams RH; Poulos A; Dubin A; Dunea G
    Adv Exp Med Biol; 1987; 223():197-204. PubMed ID: 3447436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease of polymorphonuclear leukocyte membrane fluidity in uremic patients on hemodialysis.
    Masuda M; Komiyama Y; Murakami T; Murata K
    Nephron; 1990; 54(1):36-41. PubMed ID: 2296343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ion-pair high-performance liquid chromatography profiling of a uremic toxin fraction.
    Gallice P; Monti JP; Le Gall JM; Crevat A; Murisasco A
    J Chromatogr; 1987 Nov; 422():263-6. PubMed ID: 3437013
    [No Abstract]   [Full Text] [Related]  

  • 30. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients.
    Zimmerman L; Egestad B; Jörnvall H; Bergström J
    Clin Nephrol; 1989 Sep; 32(3):124-8. PubMed ID: 2791363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemoglobin content is increased in the human erythroleukemia K562 cell line by a 56.2-kD peptide from uremic plasma.
    Fontanellas A; Navarro-Ordoñez S; Morán-Jiménez MJ; Guolo M; Franco C; García-Bravo M; Pataro L; Batlle A; de Salamanca RE
    Am J Nephrol; 2004; 24(2):230-4. PubMed ID: 15024177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietic inhibitors in uremic serum.
    Freedman MH; Grunberger T; Saunders EF
    Clin Invest Med; 1982; 5(4):237-40. PubMed ID: 7160111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-endorphin-related peptides in the human pituitary. Isolation and characterization of major immunoreactive peptides, including the formerly unrecognized peptide beta-endorphin 1-18.
    Vuolteenaho O
    Acta Physiol Scand Suppl; 1984; 531():1-84. PubMed ID: 6091413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical study for separation of middle molecules.
    Saito A; Kanazawa I; Chung TG; Maeda K
    Artif Organs; 1981; 4 Suppl():13-6. PubMed ID: 6975092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid.
    Boumendil-Podevin EF; Podevin RA; Richet G
    J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation and characterization of early pregnancy factor.
    Zuo X; Su B; Wei D
    Chin Med Sci J; 1994 Mar; 9(1):34-7. PubMed ID: 8086632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
    Dasgupta A; Jacques M
    Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 40. A uremic peptide containing polyamine: formation and possible role in uremic hypertriglyceridemia.
    Lutz W
    Physiol Chem Phys; 1980; 12(5):451-6. PubMed ID: 7010392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.